•The New England Journal of Medicine published full results of the Phase 3 TETON-2 study evaluating nebulized Tyvaso.
•The study met its primary efficacy endpoint, with nebulized Tyvaso demonstrating statistically significant improvement in absolute forced vital capacity for IPF patients.
